Effects of Ibuprofen on orthotopic glioma model in rats.

J Coll Physicians Surg Pak

Department of Neurosurgery, Izzet Baysal Hospital, Bolu, Turkey.

Published: November 2012

Objective: To determine the effects of ibuprofen (Ibp) on the vessel proliferation and necrosis in a rat glioma model.

Study Design: Experimental, randomized interventional trial.

Place And Duration Of Study: 1st Neurosurgery Clinic in Bakirkoy Mental Diseases Hospital, Bakirkoy, Istanbul, Turkey, in the year 2010.

Methodology: After stereotactic injection of C6/LacZ rat glioma cells into the Wistar rats brain, the rats were randomly assigned to two treatment groups (group 1, control; group 2, Ibp treatment). Rats were sacrificed 18 days after treatment, and number of intra-/peri-tumoural vessels, microendothelial proliferations, immunohistochemistry and necrotic area were evaluated.

Results: Ibp treatment significantly decreased tumour tissue, intratumoral vessel number and total tumour area level. The level of Ki67 was significantly decreased in the tumour tissue of group 2. Additionally, the total necrotic area / total tumour volume (%) was significantly less in the tumour tissue of the ibuprofen-treated rats compared to the controls.

Conclusion: The data show that the Ibp produced an important reduction in glioma tumour cell proliferation in the rat model.

Download full-text PDF

Source

Publication Analysis

Top Keywords

tumour tissue
12
effects ibuprofen
8
rat glioma
8
ibp treatment
8
necrotic area
8
decreased tumour
8
total tumour
8
tumour
6
rats
5
ibuprofen orthotopic
4

Similar Publications

Liver cancer poses a global health challenge with limited therapeutic options. Notably, the limited success of current therapies in patients with primary liver cancers (PLCs) may be attributed to the high heterogeneity of both hepatocellular carcinoma (HCCs) and intrahepatic cholangiocarcinoma (iCCAs). This heterogeneity evolves over time as tumor-initiating stem cells, or cancer stem cells (CSCs), undergo (epi)genetic alterations or encounter microenvironmental changes within the tumor microenvironment.

View Article and Find Full Text PDF

TRPV4 as a Novel Regulator of Ferroptosis in Colon Adenocarcinoma: Implications for Prognosis and Therapeutic Targeting.

Dig Dis Sci

January 2025

Ningxia Medical University, Xing Qing Block, Shengli Street No.1160, Yin Chuan City, 750004, Ningxia Province, People's Republic of China.

Background: Colon adenocarcinoma (COAD) is a leading cause of cancer-related mortality worldwide. Transient receptor potential vanilloid 4 (TRPV4), a calcium-permeable non-selective cation channel, has been implicated in various cancers, including COAD. This study investigates the role of TRPV4 in colon adenocarcinoma and elucidates its potential mechanism via the ferroptosis pathway.

View Article and Find Full Text PDF

Introduction: Hematologic malignancies, originating from uncontrolled growth of hematopoietic and lymphoid tissues, constitute 6.5% of all cancers worldwide. Various risk factors including genetic disorders and single nucleotide polymorphisms play a role in the pathogenesis of hematologic malignancies.

View Article and Find Full Text PDF

PMN-MDSCs are responsible for immune suppression in anti-PD-1 treated TAP1 defective melanoma.

Clin Transl Oncol

January 2025

Department of General Surgery, Guangzhou Digestive Disease Center, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, 510013, Guangdong, China.

Introduction: The transporter associated with antigen processing (TAP) is a key component of the classical HLA I antigen presentation pathway. Our previous studies have demonstrated that the downregulation of TAP1 contributes to tumor progression and is associated with an increased presence of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment. However, it remains unclear whether the elevation of MDSCs leads to immune cell exhaustion in tumors lacking TAP1.

View Article and Find Full Text PDF

Globally, the incidence and death rates associated with cancer persist in rising, despite considerable advancements in cancer therapy. Although some malignancies are manageable by a mix of chemotherapy, surgery, radiation, and targeted therapy, most malignant tumors either exhibit poor responsiveness to early identification or endure post-treatment survival. The prognosis for prostate cancer (PCa) is unfavorable since it is a perilous and lethal malignancy.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!